Kee Pharma to launch 12 bio-tech products
THE Delhi-based Kee Pharmaceuticals Ltd (KPL) is planning to launch at least 12 new products in the biotechnology segment in the next three years.
These include Recombinant Streptokinase (which dissolves intra-coronary clots to prevent fatal heart attacks), Epidermal Growth Factor (a healing and antiseptic agent for treatment of burns) and Gamma Interferon (for auto-immune diseases such as rheumato id Arthritis and sclerosis).
Other new products planned are Interferon natural and interferon alpha 2b, Recombinant Interleukin IB, Recombinant Erythropoietin, Galavit and Rabies vaccine.
``Some of these products will be launched by the Kee Pharma for the first time in India. With the launch of these products, the company will mark its presence in various therapeutic segments, especially in the field of oncology and cardiology and immunology ,'' Mr. Anil Motihar, Managing Director, KPL, told Business Line.
``Kee Pharma has already applied for the trademark registration for six new products. The first product -- Streptokinase (brand name - Cardiostrep) will be launched in September this year,'' Mr. Motihar said.
It has launched a new division `Kee Biogenetics' for its biotechnology products. It has tied up with Heber Biotec, S.A. of Cuba which is currently working on some advanced biotechnology products.
KPL has also tied up with the State Scientific Centre Research Institute, Institute of Polio Myelitis and the centre of modern medicine `Medicor' . All these institutes are acclaimed in the field of biotechnology products and vaccines in Russia.
Kee Pharma is also in talks with the Bangalore-based biotech company -- Biocon -- for a synergistic arrangement to manufacture Hepatitis B and cancer drugs in India. It is targeting a turnover of around Rs. 23 crores and a net profit of ar ound Rs. 4 crores from its biotech division in 2003-04.
No comments:
Post a Comment